Introduction
Stimulation of quiescent cells to undergo a round of cellular division is a tightly regulated process in which the cell must pass through a number of cell cycle checkpoints. The retinoblastoma protein (pRB) normally functions to restrict cell cycle progression through the G 1 stage of the cell cycle and appears to mediate one such checkpoint (Goodrich et al., 1991; Mittnacht and Weinberg, 1991; Hinds et al., 1992; Qin et al., 1992; Dowdy et al., 1993; Ewen et al., 1993) . Loss or mutation of the retinoblastoma gene is a frequently occurring event in the formation of a variety of human tumors (reviewed in Goodrich and Lee, 1993) . Two other proteins, p107 and p130, are related to pRB in structure and function (Ewen et al., 1991; Hannon et al., 1993; Li et al., 1993; Zhu et al., 1993) . These three proteins, pRB, p107 and p130, were ®rst described as targets of the adenovirus E1A oncoprotein which forms a complex with each of the RB-related proteins resulting in disruption of their normal function and deregulation of cellular growth control (reviewed in Whyte, 1995) . Oncoproteins from other DNA tumor viruses including the SV40 large T antigen and HPV E7 proteins have been shown to target the RB-related proteins in a manner analogous to E1A (DeCaprio et al., 1988; Whyte et al., 1988; Dyson et al., 1989a Dyson et al., , 1990 Ludlow et al., 1990; Imai et al., 1991; Davies et al., 1993; Wolf et al., 1995) . These observations ®rst suggested that the RB-related proteins (pRB, p107 and p130) control key checkpoints in cellular growth control. Supporting this hypothesis are observations that pRb, p107 and p130 each can suppress growth when overexpressed in certain tumor-derived cell lines (Huang et al., 1990; Goodrich et al., 1991; Templeton and Weinberg, 1991; Hinds et al., 1992; Smith and Nevins, 1995; Zhu et al., 1993 Zhu et al., , 1995a Claudio et al., 1994) . Whether p107 and p130 can function as tumors suppressor genes is unknown. To date, there are no reports of loss or mutation of either p107 or p130 in human tumors.
The growth-suppressing capabilities of pRB, p107 and p130 are due, at least in part, to the interactions these proteins have with cellular proteins. Particularly noteworthy among these are the interactions with the E2F/DP family of transcription factors (Cao et al., 1992; Devoto et al., 1992; Helin et al., 1992 Helin et al., , 1993 Kaelin et al., 1992; Shan et al., 1992; Shirodkar et al., 1992; Cobrinik et al., 1993; Ivey-Hoyle et al., 1993; Lees et al., 1993; Bandara et al., 1994; Bejersbergen et al., 1994; Ginsberg et al., 1994; Buck et al., 1995; Hijmans et al., 1995; Ormondroyd et al., 1995; Sardet et al., 1995; Wu et al., 1995; Zhang and Chellappan, 1995) . The E2F transcription factors are thought to control expression of a number of genes involved in cell cycle progression (reviewed in Cobrinik, 1996) . The interactions between the Rb family members and E2F members eectively inhibit E2F-mediated transactivation (Hamel et al., 1992; Heibert et al., 1992; Weintraub et al., 1992; Zamanian and LaThangue, 1992; Flemington et al., 1993; Helin et al., 1993; Schwartz et al., 1993; Zamanian and LaThangue, 1993; Zhu et al., 1993; Beijersbergen et al., 1994; Ginsberg et al., 1994; Johnson, 1995; Smith and Nevins, 1995; Vairo et al., 1995) . Interactions involving pRB or p107 and various other cellular proteins, including other transcription factors, also have been described (reviewed in Whyte, 1995) . In almost all cases involving interactions with pRB, phosphorylation of pRB abrogates the interaction. For example, phosphorylation of pRB results in its dissociation from E2F transcription factors (Chellappan et al., 1991; Helin et al., 1992; Shan et al., 1992; Ewen et al., 1993; Dynlacht et al., 1994; Bremner et al., 1995; Suzuki-Takahashi et al., 1995) and from E1A, T antigen and E7 (Ludlow et al., 1990; Imai et al., 1991; Templeton and Weinberg, 1991) . Phosphorylation of p107 appears to regulate its association with E2F proteins in a manner analogous to pRB (Bejersbergen et al., 1995; Xiao et al., 1996) . P130 exists in several phosphorylated states (Baldi et al., 1995; Mayol et al., 1995; Li et al., manuscript in prep.) but it is yet unknown how phosphorylation aects any of its functions or interactions.
Phosphorylation of pRB occurs in a cell cycledependent manner and is attributed to the action of cyclin-dependent kinases (cdk's). During normal cellular growth phosphorylation of pRB is thought to inhibit its growth restricting function and allow cell cycle progression. A variety of experimental evidence supports a model in which pRb is phosphorylated in vivo by the sequential action of cyclin D/cdk4 and cyclin D/cdk6 initially and, at later points in the cell cycle, by cyclin E/cdk2 and cyclin A/cdk2 complexes (Hinds et al., 1992; Dowdy et al., 1993; Ewen et al., 1993; Kato et al., 1993; Hatakeyama et al., 1994; Mittnacht et al., 1994) . Cyclin D/cdk4 or cdk6 complexes form during G1 following the growth factor-dependent transcription of the D cyclins, whereas cyclin E/cdk2 complexes form late in G 1 and cyclin A/cdk2 complexes become prominent at the onset of S-phase (reviewed in Pines, 1995) . P107 and p130 are also phosphorylated in a cell cycle dependent manner and may be substrates for cyclin D/cdk4 and cdk6 kinase activity (Baldi et al., 1995; Beijersbergen et al., 1995; Mayol et al., 1995; Xiao et al., 1996) . In the absence of a kinase partner, the D cyclins can form stable interactions with pRB and p107 through LXCXE motifs located at the N-termini of the D cyclins (Dowdy et al., 1993; Ewen et al., 1993; Hinds et al., 1994) . The motifs are reminiscent of a region of the viral oncoproteins that are required for interactions with the pRB-related proteins. P130 has been shown to interact in vitro with D cyclins, presumably through a similar mechanism . Cyclin D/cdk4 complexes have been shown to phosphorylate pRB and p107 in vitro (Dowdy et al., 1993; Ewen et al., 1993; Kato et al., 1993; Li et al., 1993; Matsushime et al., 1994) and overexpression of D cyclins supports the phosphorylation of pRB, p107 and p130 in vivo Kato et al., 1993; Beijersbergen et al., 1995; Xiao et al., 1996; our unpublished results) .
In addition to the interactions with the D cyclins, p107 and p130 stably interact with cyclin A/cdk2 and cyclin E/cdk2 complexes in vivo and in vitro Faha et al., 1992 Faha et al., , 1993 Lees et al., 1992; Hannon et al., 1993; Li et al., 1993; Peeper et al., 1993) . This property is not held in common with pRB and the signi®cance of this dierence remains unclear. Although p107 and p130 are substrates of these cyclin/ cdk2 complexes in vitro, it is not clear whether the sole purpose of these interactions is to function as a kinasesubstrate interaction. The stability of the interactions seems to indicate otherwise. It is possible that p107 and p130 serve as regulators of the cyclin/cdk2 activity or as bridges to other substrate proteins. In recent years, an increasing number of proteins have been found to associate with cyclin/cdk complexes. In some cases a regulatory role has been postulated, in other cases the functional basis of the interaction remains unknown.
For p107, the structural basis for the interactions with cyclins A and E has been examined and it has been determined that in vitro interactions between cyclin A and p107 are mediated by a part of p107 referred to as the spacer region Faha et al., 1992) . In this report, we examine the basis for the interactions between p130 and cyclin A and cyclin E complexes and identify a region of p130 required for binding to cyclin A/cdk2 and cyclin E/cdk2 complexes in vitro and in vivo.
Results
Cyclin A/cdk2 and cyclin E/cdk2 complexes interact with distinct forms of p130
When cyclin A or cyclin E is immunoprecipitated under the appropriate conditions p130 co-precipitates with the cyclin complex ( Figure 1 ; Hannon et al., 1993; Li et al., 1993) . Several dierentially migrating forms of p130 were immunoprecipitated with an antibody against the C-terminus of p130. The two faster migrating bands have been con®rmed to be p130 using other antibodies to dierent regions of p130 (data not shown). The most slowly migrating form is of undetermined origin and may represent either an altered form of p130 or a cross reacting protein. Consistent with previous observations, p130 was detected in complexes immunoprecipitated with monoclonal antibodies to cyclins A and E (Figure 1 ). In this experiment and those that follow, two previously undescribed monoclonal antibodies, 168 and 276 were used to immunoprecipitate cyclin E. Both of the faster migrating forms of p130 were present in immunoprecipitations using the cyclin E antibody 276; however, only the slower migrating form of p130 was present in immunoprecipitates using cyclin E antibody 168. The reason for this dierence is not clear but binding of antibody 168 to cyclin E may be sterically incompatible with binding of one of the p130 species. Only the faster migrating form of p130 was detected in complexes immunoprecipitated with the antibody to cyclin A. Immunoprecipitates from C33A cells using an antipeptide antisera to the carboxyl terminus of p130 (p130 CT), monoclonal antibodies to cyclin A (C160) or cyclin E (168 and 276) and rabbit anti-mouse (RAM) serum as a negative control were separated by SDS ± PAGE, transferred to nitrocellulose and immunoblotted with C20, an anti-serum raised to a p130 peptide p130 cyclin-binding region S Lacy and P Whyte
Interaction of the p130 spacer region with cyclins A and E in vitro
To assay the ability of dierent regions of p130 to interact with cyclin/cdk complexes, an in vitro system using baculovirus produced cyclins and cdk2 was established. Baculoviruses expressing human cyclin A, cyclin E or cdk2 were used to produce these proteins in insect SF9 cells and complexes containing cyclin A and cdk2 or cyclin E and cdk2 were produced by coinfecting cells with the respective baculoviruses.
Proteins of the expected sizes were readily detectable following immunoprecipitation from 35 S-radiolabeled extracts of infected SF9 cells (Figure 2a , lanes 1 ± 3 and 5 ± 9) but not from extracts of uninfected cells ( Figure  2a , lanes 4 and 10 ± 12). Cyclin A and cyclin E migrate as doublets and both bands are recognized by the appropriate antibodies. Cyclin A/cdk2 and cyclin E/ cdk2 complexes were detected in extracts from coinfected cells; however, the proportion of each of the proteins participating in the complex formation was somewhat lower than we expected. Nonetheless, these complexes proved suitable for studying interactions with p130, as described below.
To de®ne the region(s) of p130 mediating the interactions with cyclin A and cyclin E, four plasmids encoding GST-p130 fusion proteins were constructed. Each p130 fusion protein is named according to which p130 amino acids are fused in frame with GST ( Figure  2b ). The four GST-p130 fusion proteins together represent the full length of p130. To determine which GST-p130 fusion proteins could mediate interactions with the SF9-produced cyclin/cdk2 complexes, an in vitro binding assay was performed. S-labeled SF9 cell lysates containing cyclin A, cyclin A/cdk2, cyclin E or cyclin E/cdk2. Lysates were mixed with each of the four Sepharose-bound GST-p130 fusion proteins as indicated (lanes 1 ± 14) and GST alone (lanes 15 and 16). Immunoprecipitations using antibodies to cyclin A and cyclin E were included as controls (lanes 17 and 18). Complexes bound to the glutathione Sepharose beads were resolved by SDS ± PAGE and detected by autoradiography (lanes 17 and 18) p130 cyclin-binding region S Lacy and P Whyte from cells infected with combinations of baculoviruses were mixed with each GST-p130 fusion protein or GST alone. GST alone, GST-130 (1 ± 320), (339 ± 595) and (787 ± 1139) each failed to interact with either cyclin A/ cdk2 or cyclin E/cdk2 complexes ( Figure 2c , lanes 1 ± 9). In contrast, GST-p130 (593 ± 1139) interacted speci®cally with both cyclin A/cdk2 and cyclin E/ cdk2 complexes (Figure 2c, lanes 11, 13) . This result suggested that p130 residues 593 ± 1139 contain a cyclin binding domain. Although fusion proteins 593 ± 1139 and 787 ± 1139 both contain the same p130 carboxylterminal sequences, 593 ± 1139 contains additional sequences which include the spacer region. These results imply that sequences within amino acids 593 ± 786 are necessary for the interactions with cyclin/cdk2 complexes.
When lysates from co-infected cells were used, both the cyclin and cdk2 were present in the complexes formed with GST-130 (593 ± 1139) ( Figure 2c , lanes 11, 13). Interestingly, cyclin E was eciently precipitated from lysates containing either cyclin E alone or cyclin E and cdk2 ( Figure 2c , lanes 12, 13). In contrast, only a low level of cyclin A bound to GST-p130 (593 ± 1139) when a lysate containing only cyclin A was used. Substantially more cyclin A was bound when the cyclin A/cdk2 co-infected lysate was used ( Figure 2c , compare lanes 10 and 11). This raised the question of whether cyclins complexed to cdk2 interacted more eciently than uncomplexed cyclins.
Cyclin A, but not cyclin E, requires cdk2 to bind GSTp130
A series of titration experiments were conducted to determine if the interactions between cyclin A or cyclin E and GST-p130 (593 ± 1139) were dependent upon the presence of cdk2. Constant amounts of GST alone, GST-p130 (593 ± 1139) or anti-cdk2 antisera were mixed with increasing amounts of cdk2-containing SF9 lysate. In the absence of a cyclin, cdk2 did not interact detectably with either GST alone or the GSTp130 (593 ± 1139) fusion protein indicating that this region of p130 does not detectably interact with cdk2 ( Figure 3a , lanes 1 ± 12). A similar experiment conducted with increasing amounts of cyclin Econtaining SF9 lysate indicated that cyclin E binds the fusion protein in the absence of cdk2 ( Figure 3b , lanes 7 ± 12). Under the conditions of this experiment, the interaction between the GST-p130 fusion protein and cyclin E was linearly dependent on the amount of cyclin E added and the GST-130 fusion protein bound cyclin E as eciently as the 276 monoclonal antibody. When cdk2 was present with cyclin E in the lysate it neither enhanced nor inhibited the interaction with the GST-p130 fusion protein (data not shown). These results suggest that cyclin E can bind eciently to amino acids 593 ± 1139 or p130 in the absence or presence of cdk2. In contrast to the results obtained for cyclin E, GST-p130 (593 ± 1139) did not eciently interact with cyclin A even when cyclin A was present in high quantities (Figure 3c , lanes 7 ± 12). To investigate whether the cyclin A/p130 interaction was dependent on the presence of cdk2, increasing amounts of cdk2-containing lysate were mixed with a constant amount of cyclin A-containing lysate and incubated with GSTp130 (593 ± 1139). The addition of cdk2-infected SF9 lysate greatly enhanced the eciency of complex formation between the p130 fusion protein and cyclin A ( Figure 3d ). As levels of cdk2 increased, so did binding of cyclin A to the p130 fusion protein ( Figure  3d , lanes 1 ± 6). Levels of cyclin A and cdk2 present in lysates were monitored in parallel by immunoprecipitations with anti-cyclin A and anti-cdk2 antibodies ( Figure 3d , lanes 7 ± 18). This data demonstrates that in contrast to cyclin E, cyclin A can eciently interact with GST-p130 (593 ± 1139) only when complexed with its kinase partner, cdk2. In this and other experiments, we observed a slight increase in levels of cdk2 complexed to cyclin A and cyclin E in the in vitro binding assay using GST-p130 (593 ± 1139) as compared to the interactions detected by co-immunoprecipitation. One possibility is that GST-p130 (593 ± 697) stabilizes cyclin/cdk2 complexes.
To ensure that cyclin E was not interacting with GST-p130 (593 ± 1139) due to the presence of endogenous insect cdk's, p13 suc1 beads were used to pre-clear cdk-type molecules from the cyclin E-infected SF9 cell lysate. p13 suc1 is a subunit of S pombe p34 cdc2 and binds cdc2 and cdk2 with high anity (Brizuela et al., 1987) . Preclearing cyclin E-infected SF9 cells by incubation with p13 suc1 beads did not reduce the interaction of cyclin E with GST-p130 (593 ± 1139) (data not shown). This suggests that insect cell cdk's do not signi®cantly contribute to the GST-p130/cyclin E interaction.
Identi®cation of p130 sequences required for cyclin interactions
The above data suggests that p130 contains a cyclin binding region within amino acids 593 ± 1139 and that amino acids 593 ± 786 are required for this interaction (Figure 2c ). To further delineate which residues of p130 mediate the interaction between p130 and cyclins A and E, plasmids encoding ®ve additional GST-p130 fusion proteins were constructed. These fusion proteins encoded p130 amino acids 593 ± 790, 593 ± 698, 635 ± 698, 652 ± 698 and 593 ± 675 (Figure 4a S-methionine labeled SF9 cells infected with the indicated baculoviruses were lysed and mixed with the indicated GST-p130 fusion protein (lanes 2 ± 6, 10 ± 14) or GST alone (lanes 1 and 9). Complexes were analysed as described in Figure 2c and compared to immunoprecipitations of cyclin A and cyclin E from infected SF9 cells with antibodies C160 and 276, respectively (lanes 7 and 8) lysates containing cyclin A/cdk2 or cyclin E/cdk2 complexes and assayed for its ability to bind to the cyclin/cdk2 complexes. All of the fusion proteins except GST-p130 (593 ± 675) were capable of interacting with both cyclin A/cdk2 and cyclin E/cdk2 (Figure 4b ). The smallest GST-p130 fusion protein capable of interacting with cyclin A/cdk2 or cyclin E/cdk2 complexes contained p130 amino acids 652 ± 698, indicating that this region of p130 is sucient for interacting with either of the cyclin complexes. A fusion protein containing p130 amino acids 593 ± 675 failed to interact with either cyclin/cdk2 complex further suggesting that residues 652 ± 675 are not sucient for cyclin binding and that residues 676 ± 698 are critical for the interactions. As observed previously, all GST-p130 fusion proteins which retained the ability to interact with cyclin/cdk2 complexes eciently interacted with cyclin E (but not cyclin A) in the absence of cdk2 (data not shown).
Alignment of p130 amino acids 652 ± 697 with the homologous region of p107 (amino acids 576 to 787) revealed two clusters of conserved amino acids ( Figure  5a ). P130 residues 669 ± 673 (RYSSP) and residues 679 ± 685 (RRRLFVE) are relatively well-conserved within p107 sequences raising the possibility that these regions might be important for the interactions with the cyclin complexes. To address this possibility, the p130 nucleotides encoding the residues RYSSP and RRL were deleted from the p130 sequence using M13 oligonucleotide-directed mutagenesis. Three additional GST-p130 (593 ± 698) fusion proteins were constructed, containing deletions of amino acids 669 ± 673 (DRYSSP), amino acids 680 ± 682 (DRRL) or both deletions (DRYSSP/RRL). The three fusion proteins were then tested for binding to cyclin A/cdk2 and cyclin E/cdk2 complexes (Figure 5b ). The DRYSSP mutant retained the ability to bind both cyclin A and E complexes in a manner equivalent to the non-mutated GST-p130 (593 ± 698) (Figure 5b , lanes 4 ± 5), demonstrating that this conserved region is not critical for the interactions with cylin/cdk2 complexes. In contrast, the DRRL and DRYSSP/RRL mutants each failed to form complexes with cyclin A/cdk2 and cyclin E/cdk2 complexes (lanes 1 ± 3 and 7 ± 9). These observations suggest that the conserved region centered around the RRL residues plays a major role in the interactions with cyclin A/cdk2 and cyclin E/cdk2.
P130 amino acids interacting with cyclins are conserved in other cyclin-binding proteins
Conservation in p130 and p107 of the small region which apparently mediates the p130/cyclin interactions raised the possibility that these sequences might be present in other proteins known to interact with cyclin/ cdk complexes. An examination of the sequences of various other cyclin/cdk interacting proteins revealed sequences similar to the p130 RRRLFVE motif in several other proteins including E2F-1, 2 and 3, p21 cip1 , p27 kip1 and p57 kip2 (Helin et al., 1992; Kaelin et al., 1992; Shan et al., 1992; El-Deiry et al., 1993; Gu et al., 1993; Harper et al., 1993; Ivey-Hoyle et al., 1993; Lees et al., 1993; Xiong et al., 1993; Polyak et al., 1994; Toyoshima and Hunter, 1994; Lee et al., 1995; Matsuoka et al., 1995) (Figure 5a ). As discussed below, each of these proteins has been shown to be present in complexes containing cyclin A or E. In some cases, this particular region has been implicated in the cyclin interactions.
GST-p130 (593 ± 698) DRRL is a poor substrate of cyclin/cdk2 complexes To understand the consequences of the DRRL mutation on phosphorylation by cyclin/cdk2 complexes, in vitro kinase assays were performed. GSTp130 (593 ± 698) and the DRRL, DRYSSP, DRRL/ DRYSSP derivatives were incubated in the presence of , p27 Kip1 and p57
Kip2
. Amino acids present within each of these regions are as follows: p130 (674 ± 685), p107 (652 ± 663), E2F-1 (84 to 95), E2F-2 (81 to 92), E2F-3 (128 to 140), p21 cip1 (13 ± 24); p27 kip1 (24 ± 35), p57 kip2 (25 ± 36). (b) The eect that loss of p130 amino acids 669 ± 673, 680 ± 682 has on cyclin binding in vitro was examined by incubating GST-p130 (593 ± 675), DRYSSP, DRRL and DRYSSP/RRL with SF9 cell lysates containing cyclin A/cdk2 or cyclin E/cdk2 complexes exactly as in Figure 2c p130 cyclin-binding region S Lacy and P Whyte uninfected-, cyclin A/cdk2-or cyclin E/cdk2-infected SF9 cell lysates and gamma [ 32 P]-ATP. Phosphorylated proteins were then analysed by SDS ± PAGE. None of the fusion proteins were detectably phosphorylated by uninfected SF9 cell lysates (Figure 6a, lanes 1 ± 5) . GST-p130 (593 ± 698) and the DRYSSP mutant were eciently phosphorylated by cyclin A/cdk2 and cyclin E/cdk2 complexes produced in infected SF9 cells (Figure 6a, lanes 7, 9, 12 and 14) . In contrast, GST fusion proteins containing the DRRL deletion alone or in combination with the DRYSSP mutation were very poor substrates for both cyclin/cdk2 complexes (lanes 8, 10, 13 and 15). The data from the kinase assays could be explained by at least two possibilities: (1) p130 fusion proteins lacking RRL were poor cdk2 substrates because a stable interaction with cyclin/cdk2 complexes did not occur or (2) deletion of RRL resulted in alteration of a cdk2 phosphorylation site. To determine whether removal of RRL resulted in alteration of a cdk2 phosphorylation site, cyclin A/ cdk2-phosphorylated GST-p130 (593 ± 698) and the DRRL mutant were excised from the gel and subjected to phosphopeptide analysis. Each fusion protein was digested with TPCK-trypsin followed by separation of the peptide fragments by electrophoresis in the ®rst dimension and chromatography in the second dimension (Figure 6b ). The analysis revealed the presence of ®ve major phosphopeptides which were conserved betweeen GST-p130 (593 ± 698) and the DRRL mutant. This data suggested that deletion of RRL did not result in the destruction of a cdk2 consensus site. We conclude that poor phosphorylation of DRRL mutants resulted from a failure of the mutants to form stable interactions with cyclin/cdk2 complexes. In the absence of this stable interaction, cyclins A and E were unable to eciently target cdk2 to the GST-p130 substrate.
P130 D620 ± 697 is unable to bind cyclins in vivo To determine if p130 residues surrounding the RRL motif mediate cyclin A/cdk2 and cyclin E/cdk2 binding in vivo, a p130 mutant was constructed containing a deletion of amino acids 620 ± 697. The p130 mutant, p130 (D620 ± 697), was expressed under the control of the human CMV early enhancer/promoter. The ability of this p130 mutant to interact with cyclins A and E was tested by transfecting the plasmid into C33A cells and immunoprecipitating with antibodies to p130, cyclin A and cyclin E. P130 was immunoprecipitated from cells transfected with pCMV-Bam-Neo (Figure 7 , lanes 7 ± 9) or with the same vector expressing a full length p130 cDNA (pCMV-130) (lanes 4 ± 6). P130 (D620 ± 697) was immunoprecipitated, in addition to the endogenous p130, from transfected C33A cells using a p130 C-terminal antibody. The p130 (D620 ± 697) mutant protein migrated as a 120 kDa band (lane 3) and was easily distinguished from the endogenous p130. Levels of expression of transfected p130 and p130 (D620 ± 697) were comparable ( Figure 7, lanes 3,  6) . In contrast to the normal p130, the D620 ± 697 mutant did not co-immunoprecipitate with either cyclins A or E (lanes 1 and 2). This indicates that the region of p130 required for cyclin A/cdk2 and cyclin E/cdk2 interactions in vitro is also necessary for similar interactions in vivo. 5) and cells co-infected with cyclin A/cdk2 (lanes 6 ± 10) and cyclin E/ cdk2 (lanes 11 ± 15) were used to phosphorylate GST-p130 (593 ± 698) and the three deletion mutants derived from it (DRRL, DRYSSP and DRYSSP/RRL), as described in Materials and methods. (b) Protein bands corresponding to cyclin A/cdk2-phosphorylated GST-p130 (593 ± 698) and the DRRL mutant were excised and subjected to phosphopeptide analysis. Phosphopeptide maps of GST-p130 (593 ± 698) (left) and the DRRL mutant (right) following electrophoresis (horizontal) and ascending chromatography (vertical) are shown. The origin is represented as a spot at the bottom left-hand corner of each ®gure When overexpressed, p130 can suppress the growth of certain cell lines (Claudio et al., 1994; G Culp and P Whyte, unpublished) . To determine if binding to cyclin A and cyclin E complexes is critical to its growth suppressing capacity, p130 and the D620 ± 697 mutant were assayed for growth suppression in C33A and SAOS-2 cells. p130, p130 (D620 ± 697), p107 and pRb along with a neomycin resistance marker (neo r ) were transfected into cells and G418-resistant colonies were selected over a 3 week period. The number of colonies observed for cells transfected with each of the plasmids is expressed as a percentage of neo r ( Figure  8 ). PRb and p107 each reduced colony formation to 8 ± 10% in SAOS-2 cells and to 2 ± 3% in C33A cells as compared to neo r alone. On average, wild type p130 suppressed colony formation to 43% in SAOS-2 cells and to 25% in C33A cells. In comparison with wild type p130, p130 (D620 ± 697) suppressed growth to 9% in SAOS-2 cells and to 18% in C33A cells. Although it is not clear why the p130 mutant appears to suppress growth more eectively in SAOS-2 cells than wild type p130, the data suggests that a p130 mutant deleted in a region mediating cyclin binding in vivo retains its capacity to negatively regulate growth and may, in fact, be more potent than p130 in suppressing growth of these cells.
Discussion
Many aspects of cell cycle progression are thought to be regulated by the kinase activity of cyclin/cdk complexes. Among the cellular proteins which can be found in complexes with cyclin A/cdk2 and cyclin E/ cdk2 are p130 and p107. For p130, these interactions are dependent on the RRRLFVE sequence region which we will refer to as the cyclin binding region throughout this discussion. Several other cellular proteins which have been shown to stably interact with cyclin/cdk complexes also contain a region that is homologous to the p130 cyclin binding region. Included among these are the highly related p107 protein, the cdk inhibitors p21 cip1 , p27 kip1 , p57 kip2 (ElDeiry et al., 1993; Gu et al., 1993; Harper et al., 1993; Xiong et al., 1993; Polyak et al., 1994; Toyoshima and Hunter, 1994; Lee et al., 1995; Matsuoka et al., 1995) and the transcription factor E2F-1 (Helin et al., 1992; Kaelin et al., 1992; Shan et al., 1992) . A similar sequence is found in E2F-2 and -3; however, these proteins have not been demonstrated to interact with the cyclin/cdk complexes (Ivey-Hoyle et al., 1993; Lees et al., 1993) . The apparent conservation of the cyclin binding region suggests that it serves as a mechanism for interactions of dierent proteins with cyclin/cdk complexes. Studies on some of the above mentioned proteins have indicated that the residues homologous to the p130 cyclin binding region are directly involved in cyclin/cdk interactions. p107 has been shown to interact with both cyclins A and E and several studies have suggested that the region homologous to the p130 cyclin binding region is critical for these interactions Faha et al., 1992; Zhu et al., 1995a, b) . A region similar to the p130 cyclin binding region is found at the amino-termini of p21 cip1 , p27 kip1 and p57
kip2
. Several reports show the amino terminal region of p21 cip1 is necessary and sucient to inhibit cdk activity Goubin and Ducommun, 1995; Luo et al., 1995; Nakanishi et al., 1995; Zakut and Givol, 1995) . Substitution of p21 cip1 amino acids 21 and 24 severely disrupts its in vitro interactions with cyclin D and cyclin E (Lin et al., 1996) . Both of these residues are within the region homologous to the p130 cyclin binding region. Similarly, studies on mutants of p27 kip1 have implicated the amino terminal region as being essential for interactions with cyclin E/cdk2 complexes (Luo et al., 1995) . Substitution of amino acids within the cyclin binding region abolished the cyclin E/cdk2 interactions (Luo et al., 1995) . Evidence for the function of the conserved domain in cyclin binding has recently come from structural studies of a 69 amino acid fragment of p27 kip1 bound to cyclin A and cdk2 (Russo et al., 1996) . The structure of this complex, as determined by X-ray crystallography, implicated the LFG residues of the p27 kip1 cyclin binding region as contact residues mediating the interaction with cyclin A while other residues in p27 kip1 interacted with and inhibited the activity of cdk2. The transcription factor E2F-1 also has been shown to utilize its cyclin binding region to interact with cyclin A (Krek et al., 1994; Xu et al., 1994) . In this case the function of the interaction is to phosphorylate the E2F-1/DP1 complex and downregulate DNA binding (Dynlacht et al., 1994; Kitagawa et al., 1995; Krek et al., 1995) . Although the above-mentioned proteins all contain a conserved cyclin binding domain, they appear to target cyclins for dierent purposes. Presently, it is not apparent how speci®city of the cyclin/cdk interaction is determined. Our results imply that identical or very similar p130 sequences mediate the interactions with both cyclin A-and cyclin Econtaining complexes. Studies on E2F-1 interactions with cyclins indicate that although E2F-1 contains a cyclin binding motif that is similar to p130, it is capable of interacting only with cyclin A and not cyclin E (Dynlacht et al., 1994; Krek et al., 1994; Xu et al., 1994; Kitagawa et al., 1995) . Further diversity of cyclin interaction is observed with the cyclin binding regions of p21 cip1 , p27 kip1 and p57 kip2 (El-Deiry et al., 1993; Gu et al., 1993; Harper et al., 1993; Xiong et al., 1993; Polyak et al., 1994; Toyoshima and Hunter, 1994; Lee et al., 1995; Matsuoka et al., 1995) . These proteins have a broader speci®city range and can interact with complexes containing cyclins A, B and E and the D cyclins. It is possible that the sequence variability within the cyclin binding regions is responsible for the speci®city of the cyclin/cdk interactions.
The conservation of cyclin binding regions in several dierent proteins raises the possibility of competition for interactions with the cyclin/cdk complexes. P21 has been shown to compete with both p107 and p130 for interactions with cyclin A/ cdk2 and cyclin E/cdk2 (Zhu et al., 1995b; Shiyanov et al., 1996) . The competition for cyclin/cdk interactions may extend to kinase substrates which do not form stable interactions with cyclin/cdk complexes if this activity requires the same binding site occupied by p130, p107, p21 cip1 and p27 kip1 .
Materials and methods

Cell lines, infection and transfection
C33A (human cervical carcinoma), and SAOS-2 (human osteosarcoma) cells were purchased from American Type Culture Collection and were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) with 10% fetal bovine serum. SF9 cells were generously provided by D Johnson (McMaster University) and cultured in Grace's media supplemented with lactalbumin and yeastolate. Baculoviruses encoding cyclin A, cyclin E and cdk2 were generously provided by D Morgan, UCSF Ko et al., 1992) . SF9 cells were infected with baculoviruses at an MOI of 5 p.f.u./cell for 48 h and metabolically labeled with 0.3 mCi of [ 35 S]methionine for 3 h in Grace's methionine minus media (Gibco BRL).
Stable and transient transfections of mammalian cells were performed using the calcium phosphate precipitation technique and 10 mg of plasmid DNA per plate (Graham and Van Der Eb, 1973) . For stable transfections, 3610 5 cells/ 10 cm plate were incubated in the presence of the DNAcalcium phosphate precipitate containing 10 mg of plasmid DNA for 15 h. Cells were then washed twice with PBS and incubated with media containing 425 mg/ml G418 (Geneticin; Gibco, BRL). C33A cells were split 1 : 5 before addition of G418-containing media. Media was aspirated and replaced with fresh G418-containing media every 3 days for 3 weeks. Surviving colonies were ®xed in 10% buered formalin phosphate and stained with 4% Giemsa in PBS prior to counting. For transient transfections, cells were incubated in the presence of a DNA-calcium phosphate precipitate exactly as for stable transfections but were re-fed with DMEM plus 10% FBS and lysed 24 h later.
Antibodies
Monoclonal antibodies 168 and 276 to cyclin E were generated by injecting Balb/C mice intraperitoneally with 50 mg GST-cyclin E fusion protein. Splenocytes from immunized mice were removed and fused to NS-1 murine myeloma cells and hybridomas were selected in azaserinehypoxanthine-containing media as previously described (Harlow and Lane, 1988) . p130 CT (C-terminal) antibody was generated by injecting New Zealand white rabbits with the p130 C-terminal peptide KYLRRLQDVANDRGSH coupled to keyhole limpet hemocyanin (KLH). C20 (Santa Cruz Biotechnology) is a peptide antisera raised against p130 C-terminal amino acids ENHSALLRRLQD-VANDRGSH. Antibody C160 to cyclin A has previously been described (Giordano et al., 1989) . Cdk2 antisera was derived from the cdk2 C-terminal peptide YCGQDVTKP-VPHLRL coupled to KLH. All peptide antisera were anity puri®ed using immobilized peptide (Harlow and Lane, 1988) .
GST fusion proteins
GST-cyclin E contains cyclin E amino acids 26 ± 395 fused in-frame to glutathione-S-transferase (GST). All GST-p130 fusion proteins are named according to the p130 amino acids present within them. pGST-130 (787 ± 1139) is an SstI, XbaI fragment (nt 2440 ± 3548) blunted with Klenow and cloned into the SmaI site of pGex 1X; pGST-130 (339 ± 595) is a PCR product (nt 1087 ± 1834) derived from forward primer (5'-GCCTATGAGGAGTATGTTTTA-3') and reverse primer (5'-CCATGCCAAATGATCTAAGAT-3') blunted with Klenow and cloned into the SmaI site of pGex 3X; pGST-130 (1 ± 320) is a blunted EagI, XbaI fragment (nt 50 ± 1032) cloned into the SmaI site of pGEX 2T; pGST-130 (593 ± 1139) is a BglII to XbaI fragment (nt 1844 ± 3548) blunted with Klenow and cloned into the SmaI site of pGEX 2T; pGST-130 (593 ± 790) is a BglII, SacI fragment (nt 1844 ± 2440) blunted with Klenow and cloned into the SmaI site of pGex 2T; pGST-130 (593 ± 698) is a BglII, SphI fragment blunted with Klenow and cloned into the SmaI site of pGex 2T; pGST-130 (635 ± 698) is an ApoI, SphI fragment (nt 1967 ± 2163) blunted with Klenow and cloned into the SmaI site of pGex 2T; pGST-130 (652 ± 698) was generated by PCR using a forward primer (5'-GTGGATCCGATACTGGAGGACT-TGGA-3') and a reverse primer (5'-TACAAATGGATAG-GGA-3') and p130 cDNA as a template. The 1157 nt PCR product (nt 2023 ± 3180) was digested with SphI, Klenowed, digested with BamHI and cloned into pGEX 2T digested with BamHI and SmaI. pGST-130 (593 ± 675) was generated by PCR using the forward primer (5'-GTTCCTTACATGATG-3') and the reverse primer (5'-GACTTAAGCCGACCACCCCTCGACAT-3'). The 250 nt PCR product (nt 1844 ± 2094) was digested with BglII, EcoRI, blunted with Klenow and cloned into pGEX 2T digested with BamHI, EcoRI and Klenowed. Oligonucleotides were purchased from The Central Facility of the Institute for Molecular Biology and Biotechnology, McMaster University. pGST-130 (DRRL), (DRYSSP) and DRYSSP/RRL) were derived by blunting XbaI, SphI fragments digested from the appropriate M13Mp18 replicative form DNA and ligated into the blunted BamHI site of pGex 2T.
Expression of GST fusion proteins and in vitro binding assays
Plasmids encoding each fusion protein were transformed into the DH5a strain of E. coli. Positive clones were grown in 250 ml cultures to a suspension O.D. of 0.5, induced with 1 mM IPTG for 4 h and harvested by centrifugation. Cells were lysed in NTEN buer (100 mM NaCl 2 , 20 mM p130 cyclin-binding region S Lacy and P Whyte Tris pH 8.0, 1 mM DTT, 1 mM EDTA, 1% NP40, 1 mg/ml leupeptin and 2 mg/ml aprotinin) and sonicated for 15 s on ice. Lysates were cleared by a 10 min spin in an Eppendorf centrifuge at 48C. Crude lysates were incubated with glutathione Sepharose beads (Pharmacia), rocked at 48C for 1 h then collected by centrifugation. The beads were washed three times in NTEN buer and the bound fusion proteins were denatured in Laemmli sample buer, heated to 808C separated by electrophoresis. Quantitation of the fusion proteins was by comparison with a de®ned standard after staining with Coomassie brilliant blue.
1 mg of each GST-p130 fusion protein or 10 mg of GST alone (all bound to glutathione Sepharose) was mixed with 100 mg of cyclin A-containing 35 S-labeled SF9 cell lysates or 20 mg of cyclin E-, cdk2-or cyclin E/cdk2-containing 35 Slabeled lysates (varying levels of lysates were used owing to the dierent expression levels of the indicated baculoviruses). The mixtures were incubated for 1 h at 48C and complexes collected by centrifugation. Sepharose beads were washed three times in high salt E1A buer (500 mM NaCl 2 , 50 mM HEPES pH 7.0, 0.1% NP40, 1 mg/ml leupeptin and 2 mg/ml aprotinin) and re-suspended in 60 ul Laemmli sample buer, heated to 808C for 3 min and the supernatants analysed by SDS ± PAGE. Gels were processed for¯uorography by addition of PPO, dried and allowed to expose for 1 ± 3 days.
M13 oligonucleotide-directed mutagenesis
M13Mp18 DNA and bacterial strains MV1190 and CJ236 were kindly provided by J Capone (McMaster University). An 1131 nt XbaI/SphI p130 fragment was cloned into the XbaI/SphI site of M13Mp18 and mutagenesis carried out according to the method of Zoller and Smith with the modi®cation of Kunkel (Zoller and Smith, 1984; Kunkel, 1985) . The replicative form of this p130-containing viral DNA (p130 RF) was propagated in the MV1190 strain of E. coli following transformation of cells and plaque puri®cation. To produce uracil-containing single-stranded M13 phage (p130 SS), a 500 ml culture of E. coli strain CJ236 (dut 7 , ung 7 ) was transformed with p130 RF and grown in the presence of 0.25 mg/ml of uracil for 6 h. Single-stranded phage was isolated by ethylene glycol precipitation and viral proteins removed by multiple rounds of phenol-chloroform extraction. Uracil-containing single-stranded template was added to a reaction mixture with primer 86 (5'-GGTAGTGCTGGCTGGATCGTA-TAATGTGGT-3') to delete p130 nt's 2074 ± 2088 (DRYSSP) or primer 87 (5'-GCTATCATTCTCAA-CAAATCTGGTAGTGCTGGC-3') to delete p130 nt's 2107 ± 2115 (DRRL). Each reaction mixture also contained the M13 universal reverse primer (5'-GTAAAAC-GACGGCCAGT-3'). After allowing the polymerization/ ligation reaction to proceed, the DNA was transformed into MV1190 cells and phage DNA from individual plaques was screened for the correct deletion by sequencing. A double mutant (DRYSSP/RRL) was produced by sequential rounds of mutagenesis using the two mutagenesis primers described above. Following mutagenesis, an XbaI-SphI restriction fragment of the p130 sequence which contained the mutation was isolated from replicative form M13 DNA, blunted with Klenow and ligated into the pGEX 2T vector.
In vitro kinase assays and phosphopeptide mapping SF9 cells were infected with the indicated baculoviruses at an MOI of ®ve p.f.u./cell for 48 h followed by lysis in EIA buer plus protease inhibitors (250 mM NaCl 2 , 50 mM HEPES pH 7.0, 0.1% NP40, 2 mg/ml aprotinin, 1 mg/ml leupeptin). 10 mg of glutathione Sepharose-bound GSTp130 (593 ± 698) or mutant versions of it (DRRL, DRYSSP, DRYSSP/RRL) were incubated with 18 mg of cyclin A/ cdk2-containing SF9 cell lysate or 24 mg of cyclin E/cdk2-containing lysate. Each reaction contained 10 mCi gamma [ 32 P]ATP, 10 mM MgCl 2 and 0.5 mM ATP in a total volume of 40 ml. Samples were incubated at room temperature for 40 min, centrifuged to isolate Sepharose and washed once in E1A buer. Samples were processed for electrophoresis exactly as described below in immunoprecipitation and immunoblot analysis, except following electrophoresis gels were rinsed for 10 min in water prior to drying. Following overexposure of the gel, the autoradiograph was aligned with the gel and bands corresponding to GST-p130 (593 ± 698) and the RRL mutant were excised. Isolation and digestion of the proteins with TPCK-trypsin (Worthington Biochemical, NJ) was performed according to Boyle et al. (1991) . 5000 c.p.m. of digested protein was spotted onto a TLC glass-backed plate and separated in two dimensions. In the ®rst dimension, TLC plates were subjected to horizontal electrophoresis on a Hunter thin-layer electrophoresis system (HTLE-7000; CBS Scienti®c, Del Mar, CA) at 1500 V for 30 min in pH 1.9 buer (1 : 3 : 36 formic acid (88%): glacial acetic acid: water). In the second dimension, plates were placed in an equilibrated chromatography tank containing phospho chromotography buer (6.5 : 5 : 1 : 4 n-butanol: pyridine: glacial acetic acid: water) for 9 h. Plates were dried and exposed for autoradiography.
Plasmids pCMV-Rb and pCMV-107 have been described previously (Qin et al., 1992; Zhu et al., 1993) . pCMV-130 contains the complete p130 cDNA cloned into the BamHI site of pCMV-Bam-Neo (Baker et al., 1990) and was provided by G Culp. pCMV-130 (D620 ± 697) was created by PCR using forward primer (5'-GTTCCTTACATGATG-3') and reverse primer (5'-GCTGCATGCCACATGTAGGAA-CTCTG-3') which contains an SphI site. The 1006 nt fragment was digested with A¯II and SphI to produce a 921 nt fragment which was used to replace the A¯II-SphI fragment (nt's 1000 ± 2163) of the p130 cDNA resulting in a deletion of nucleotides 1928 ± 2160. This deletion mutant contains an extra glycine at the junction between amino acids 619 and 698. The resulting p130 (D620 ± 697) cDNA was ligated into the blunt-ended BamHI site of pCMVBam-Neo.
Immunoprecipitation and immunoblot analysis
Mammalian cells and insect cells were processed for immunoprecipitation by harvesting cells directly o plates following aspiration of media and one rinse with PBS. 1 ml of E1A buer plus protease inhibitors was added to each plate which was allowed to sit on ice for 5 min. Cells were lysed by gentle pipetting and cellular debris cleared by centrifugation. Protein concentrations were determined by a BCA protein assay (Pierce) using BSA as a standard. Appropriate antibodies, protein A Sepharose (Pharmacia) and rabbit anti-mouse antisera (in the case of monoclonals) were added to crude lysates in a total of 1 ml E1A buer. Mixtures were rocked for 1 h at 48C. Complexes bound to protein A Sepharose were collected by gentle centrifugation and the Sepharose washed three times in E1A buer. 60 ml of Laemmli sample buer was added to the Sepharose and complexes were heated for 3 min at 808C. The samples were electrophoresed on SDS-polyacrylamide gels. Following electrophoresis, gels were electroblotted onto nitrocellulose as previously described (Burnette, 1981) . Primary antibodies were incubated with the nitrocellulose in blocking solution overnight. Horseradish peroxidase-conjugated secondary antibody (Amersham) was incubated with the membrane for 1 h and the signal detected by chemiluminescence (ECL).
